Cardiff Lexington (CDIX) 주식 개요카디프 렉싱턴 코퍼레이션은 자회사와 함께 미국 내 헬스케어 산업을 운영하고 있습니다. 자세히 보기CDIX 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성2/6배당0/6위험 분석지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.cash runway 경력이 1년 미만입니다.지난 5년간 매년 수익이 27% 감소했습니다.지난 1년 동안 주주가 크게 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기CDIX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW485,335 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG485,335 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$1.50476.9% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-9m15m2016201920222025202620282031Revenue US$14.5mEarnings US$1.1mAdvancedSet Fair ValueView all narrativesCardiff Lexington Corporation 경쟁사Cryo-Cell InternationalSymbol: NYSEAM:CCELMarket cap: US$28.8mrYojbabaSymbol: NasdaqCM:RYOJMarket cap: US$33.6mConcord Medical Services HoldingsSymbol: NYSE:CCMMarket cap: US$20.8mBasel Medical GroupSymbol: NasdaqCM:BMGLMarket cap: US$9.4m가격 이력 및 성과Cardiff Lexington 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$1.5052주 최고가US$18.6952주 최저가US$0.93베타1.751개월 변동-9.09%3개월 변동-37.94%1년 변동n/a3년 변동-98.34%5년 변동-99.90%IPO 이후 변동-99.90%최근 뉴스 및 업데이트공시 • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026공시 • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offering공시 • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026공시 • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.공시 • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock공시 • Nov 07Cardiff Lexington Corporation to Report Q3, 2025 Results on Nov 14, 2025Cardiff Lexington Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 14, 2025더 많은 업데이트 보기Recent updates공시 • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026공시 • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offering공시 • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026공시 • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.공시 • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock공시 • Nov 07Cardiff Lexington Corporation to Report Q3, 2025 Results on Nov 14, 2025Cardiff Lexington Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 14, 2025공시 • Aug 15Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/14/2025, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jul 29Cardiff Lexington Corporation to Report Q2, 2025 Results on Aug 12, 2025Cardiff Lexington Corporation announced that they will report Q2, 2025 results on Aug 12, 2025공시 • May 03Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 to $6 Discount Per Security: $0.45공시 • Jun 13Cardiff Lexington Corporation Announces Executive ChangesOn June 5, 2024, Cardiff Lexington Corporation announced termination Zia Choe from her position as Chief Accounting Officer of the Company in connection with a restructuring of the Company’s accounting department. The Company’s Chief Financial Officer, Matthew T. Shafer, will serve as the Company’s principal accounting officer and the Company has hired a new Controller and Staff Accountant to support Mr. Shafer.공시 • Jan 17Cardiff Lexington Appoints Kevin Fitzgerald as Managing Director of Nova Ortho and SpineCardiff Lexington Corporation announced the appointment of Dr. Kevin Fitzgerald, M.D. as Managing Director of Nova Ortho and Spine, the Company's healthcare subsidiary. Dr. Fitzgerald has previously been with Nova Ortho and Spine as a highly qualified member of the management and care team. In his new role as managing director, he will now oversee all aspects of day to day operations, expansion, patient care, provider production, marketing, and company relations as the business continues to grow. Dr. Fitzgerald has over 20 years of experience in the medical profession in various roles including physician, respiratory therapist, and physician's assistant. From 2018 to 2021, Dr. Fitzgerald was the alternate Chief Medical Officer and the in-patient medical director for the Cleveland Clinic throughout Martin County, Florida. He also served as the Chairman of Medicine, Professional Development Physician Champion, Operations Development, Financial Committee Member, Board of Trustees (voting member), and an Instructor for Career Development and Patient Advocacy. In these roles, Dr. Fitzgerald was solely responsible for three hospitals with a total patient capacity of over 550, as well as the supervision of 30 physicians and 12 advanced care providers. Additionally, during his tenure, Dr. Fitzgerald developed several programs to include a physician advisory platform that allowed the hospital system to work closely with private and government insurance. This created a symbiotic relationship while improving care and increasing revenue. Dr. Fitzgerald also continues to serve as a Colonel and the Chief of Aerospace Medicine in the Air National Guard overseeing the state of Florida's entire health program of Aerospace and General Medicine. Dr. Fitzgerald is board certified by the American Academy for Procedural Medicine (AAOPM) for procedural medicine, certified traumatic brain injury specialist, and a life care planner for catastrophic injuries. He earned his Doctor of Medicine from the International University of Health and Sciences and completed his residency at Oakland University in Detroit, MI, a part of the Beaumont Health network, now one of the largest healthcare systems in Michigan. In addition to his medical degree, Dr. Fitzgerald has also earned a Bachelor of Science in physician assistant studies and a Master of Health Science from Nova Southeastern University, as well as a Bachelor of Science in Mass Communications from Towson University.공시 • Jan 05Cardiff Lexington Corporation Appoints Zia Choe as Chief Accounting OfficerCardiff Lexington Corporation announced the appointment of Zia Choe as Chief Accounting Officer. Ms. Choe previously served as interim Chief Financial Officer at Cardiff Lexington. In her new role, Ms. Choe will work across all constituencies to help ensure accurate and timely financial reporting, develop policies and procedures which align to enterprise-wide business strategies and accounting professional standards, perform technical accounting diligence on prospective acquisitions, and support on the execution of the Company's strategic growth initiatives to expand on a national scale. Ms. Choe is a highly accomplished finance professional with 17 years of accounting and operational experience. Most recently, Ms. Choe served as a Partner at STK Financial where she was responsible for the financial audit and review of domestic and international clients, provided high level outsourced accounting advisory services, performed financial due diligence for mergers and acquisitions, and assisted in the preparation of 10K and 10Q financial statements and footnotes. Prior to this role, Ms. Choe served as Audit and Assurance Manager at JNK Accountancy Group, where she successfully conducted financial audits in accordance with US GAAP and IFRS measures for various domestic and international clients. She also advised clients on various topics including accounting policies, internal control, risk assessments, fraud, and new accounting standards. Ms. Choe is a certified public accountant. She received her Bachelor of Science degree in hospitality management from Florida International University and her Master of Science equivalent in accounting from the AICPA Accounting Program at Ajou University in Suwon, South Korea.공시 • May 25Cardiff Lexington Corp. announced delayed 10-Q filingOn 05/24/2023, Cardiff Lexington Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 25Cardiff Lexington Corporation announced delayed amended 10-Q filingOn 08/24/2021, Cardiff Lexington Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.공시 • Aug 17Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/16/2021, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 05Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million on June 4, 2021. Under the terms, Cardiff paid $2.5 million in cash, 0.9 million J Preferred Stock and a performance based contingent supplement payment of 0.8 million shares. Leonite Capital and an affiliated institutional investor provided a capital investment into Cardiff Lexington Series N Preferred Stock of $3.5 million which facilitated Cardiff Lexington's cash payment portion of the acquisition to the Sellers. No operational changes are planned, and current ownership will remain in place under a ten (10) year Management Agreement. The subsidiary will serve as an acquisition platform to integrate complementary healthcare service providers in neighboring markets and ancillary service providers (chiropractic, physical therapy, imaging, etc.) as we meet rapidly expanding opportunities. Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.주주 수익률CDIXUS HealthcareUS 시장7D0%0.3%-0.4%1Yn/a29.8%18.4%전체 주주 수익률 보기수익률 대 산업: CDIX의 US Healthcare 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: CDIX의 US 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is CDIX's price volatile compared to industry and market?CDIX volatilityCDIX Average Weekly Movement27.4%Healthcare Industry Average Movement7.3%Market Average Movement7.3%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.2%안정적인 주가: CDIX의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: CDIX의 주간 변동성은 지난 1년간 77%에서 27%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트n/a17Alex Cunninghamcardifflexington.com카디프 렉싱턴 코퍼레이션은 자회사와 함께 미국의 헬스케어 산업에서 사업을 운영하고 있습니다. 이 회사는 헬스케어와 부동산의 두 부문으로 운영됩니다. 골격계 및 관련 뼈, 관절, 힘줄, 근육, 인대, 신경의 부상과 장애에 대한 다양한 진단 및 수술 서비스를 제공합니다.더 보기Cardiff Lexington Corporation 기초 지표 요약Cardiff Lexington의 순이익과 매출은 시가총액과 어떻게 비교됩니까?CDIX 기초 통계시가총액US$22.92m순이익 (TTM)-US$9.45m매출 (TTM)US$10.84m2.1x주가매출비율(P/S)-2.4x주가수익비율(P/E)CDIX는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표CDIX 손익계산서 (TTM)매출US$10.84m매출원가US$4.16m총이익US$6.68m기타 비용US$16.13m순이익-US$9.45m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-0.62총이익률61.65%순이익률-87.14%부채/자본 비율363.8%CDIX의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/08 04:29종가2026/07/08 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cardiff Lexington Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026
공시 • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offering
공시 • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026
공시 • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.
공시 • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock
공시 • Nov 07Cardiff Lexington Corporation to Report Q3, 2025 Results on Nov 14, 2025Cardiff Lexington Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 14, 2025
공시 • May 14Cardiff Lexington Corporation to Report Q1, 2026 Results on May 19, 2026Cardiff Lexington Corporation announced that they will report Q1, 2026 results on May 19, 2026
공시 • May 01Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $5.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,739,130 Price\Range: $3.45 Discount Per Security: $0.276 Transaction Features: Sponsor Backed Offering
공시 • Mar 12Cardiff Lexington Corporation to Report Q4, 2025 Results on Mar 16, 2026Cardiff Lexington Corporation announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Mar 16, 2026
공시 • Jan 06Cardiff Lexington Corporation Announces Board Changes, Effective December 31, 2025On December 31, 2025, Daniel Thompson resigned from the Board of Directors of Cardiff Lexington Corporation (the “ Company”), including from his position as Chairman of the Board. Such resignation was not due to any disagreement with the Company on any matter relating to its operations, policies (including accounting or financial policies) or practices. Alex Cunningham, the Company’s Chief Executive Officer and member of the Board of Directors, was appointed as the new Chairman of the Board.
공시 • Dec 16Cardiff Lexington Corporation has filed an IPO in the amount of $6 million.Cardiff Lexington Corporation has filed an IPO in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock
공시 • Nov 07Cardiff Lexington Corporation to Report Q3, 2025 Results on Nov 14, 2025Cardiff Lexington Corporation announced that they will report Q3, 2025 results Pre-Market on Nov 14, 2025
공시 • Aug 15Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/14/2025, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jul 29Cardiff Lexington Corporation to Report Q2, 2025 Results on Aug 12, 2025Cardiff Lexington Corporation announced that they will report Q2, 2025 results on Aug 12, 2025
공시 • May 03Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million.Cardiff Lexington Corporation has withdrawn its IPO in the amount of $9.6 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 to $6 Discount Per Security: $0.45
공시 • Jun 13Cardiff Lexington Corporation Announces Executive ChangesOn June 5, 2024, Cardiff Lexington Corporation announced termination Zia Choe from her position as Chief Accounting Officer of the Company in connection with a restructuring of the Company’s accounting department. The Company’s Chief Financial Officer, Matthew T. Shafer, will serve as the Company’s principal accounting officer and the Company has hired a new Controller and Staff Accountant to support Mr. Shafer.
공시 • Jan 17Cardiff Lexington Appoints Kevin Fitzgerald as Managing Director of Nova Ortho and SpineCardiff Lexington Corporation announced the appointment of Dr. Kevin Fitzgerald, M.D. as Managing Director of Nova Ortho and Spine, the Company's healthcare subsidiary. Dr. Fitzgerald has previously been with Nova Ortho and Spine as a highly qualified member of the management and care team. In his new role as managing director, he will now oversee all aspects of day to day operations, expansion, patient care, provider production, marketing, and company relations as the business continues to grow. Dr. Fitzgerald has over 20 years of experience in the medical profession in various roles including physician, respiratory therapist, and physician's assistant. From 2018 to 2021, Dr. Fitzgerald was the alternate Chief Medical Officer and the in-patient medical director for the Cleveland Clinic throughout Martin County, Florida. He also served as the Chairman of Medicine, Professional Development Physician Champion, Operations Development, Financial Committee Member, Board of Trustees (voting member), and an Instructor for Career Development and Patient Advocacy. In these roles, Dr. Fitzgerald was solely responsible for three hospitals with a total patient capacity of over 550, as well as the supervision of 30 physicians and 12 advanced care providers. Additionally, during his tenure, Dr. Fitzgerald developed several programs to include a physician advisory platform that allowed the hospital system to work closely with private and government insurance. This created a symbiotic relationship while improving care and increasing revenue. Dr. Fitzgerald also continues to serve as a Colonel and the Chief of Aerospace Medicine in the Air National Guard overseeing the state of Florida's entire health program of Aerospace and General Medicine. Dr. Fitzgerald is board certified by the American Academy for Procedural Medicine (AAOPM) for procedural medicine, certified traumatic brain injury specialist, and a life care planner for catastrophic injuries. He earned his Doctor of Medicine from the International University of Health and Sciences and completed his residency at Oakland University in Detroit, MI, a part of the Beaumont Health network, now one of the largest healthcare systems in Michigan. In addition to his medical degree, Dr. Fitzgerald has also earned a Bachelor of Science in physician assistant studies and a Master of Health Science from Nova Southeastern University, as well as a Bachelor of Science in Mass Communications from Towson University.
공시 • Jan 05Cardiff Lexington Corporation Appoints Zia Choe as Chief Accounting OfficerCardiff Lexington Corporation announced the appointment of Zia Choe as Chief Accounting Officer. Ms. Choe previously served as interim Chief Financial Officer at Cardiff Lexington. In her new role, Ms. Choe will work across all constituencies to help ensure accurate and timely financial reporting, develop policies and procedures which align to enterprise-wide business strategies and accounting professional standards, perform technical accounting diligence on prospective acquisitions, and support on the execution of the Company's strategic growth initiatives to expand on a national scale. Ms. Choe is a highly accomplished finance professional with 17 years of accounting and operational experience. Most recently, Ms. Choe served as a Partner at STK Financial where she was responsible for the financial audit and review of domestic and international clients, provided high level outsourced accounting advisory services, performed financial due diligence for mergers and acquisitions, and assisted in the preparation of 10K and 10Q financial statements and footnotes. Prior to this role, Ms. Choe served as Audit and Assurance Manager at JNK Accountancy Group, where she successfully conducted financial audits in accordance with US GAAP and IFRS measures for various domestic and international clients. She also advised clients on various topics including accounting policies, internal control, risk assessments, fraud, and new accounting standards. Ms. Choe is a certified public accountant. She received her Bachelor of Science degree in hospitality management from Florida International University and her Master of Science equivalent in accounting from the AICPA Accounting Program at Ajou University in Suwon, South Korea.
공시 • May 25Cardiff Lexington Corp. announced delayed 10-Q filingOn 05/24/2023, Cardiff Lexington Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 25Cardiff Lexington Corporation announced delayed amended 10-Q filingOn 08/24/2021, Cardiff Lexington Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.
공시 • Aug 17Cardiff Lexington Corporation announced delayed 10-Q filingOn 08/16/2021, Cardiff Lexington Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 05Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million on June 4, 2021. Under the terms, Cardiff paid $2.5 million in cash, 0.9 million J Preferred Stock and a performance based contingent supplement payment of 0.8 million shares. Leonite Capital and an affiliated institutional investor provided a capital investment into Cardiff Lexington Series N Preferred Stock of $3.5 million which facilitated Cardiff Lexington's cash payment portion of the acquisition to the Sellers. No operational changes are planned, and current ownership will remain in place under a ten (10) year Management Agreement. The subsidiary will serve as an acquisition platform to integrate complementary healthcare service providers in neighboring markets and ancillary service providers (chiropractic, physical therapy, imaging, etc.) as we meet rapidly expanding opportunities. Cardiff Lexington Corporation (OTCPK:CDIX) acquired Nova Ortho and Spine, LLC for $9.3 million.
